Regeneron Pharmaceuticals, Inc.
Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –
Regeneron Pharmaceuticals Customer Accounts Receivable Concentration by Year
Customer Accounts Receivable Concentration — Top Specialty Distributors Share of Trade AR [annual] (%) (%)
Regeneron Pharmaceuticals Customer Accounts Receivable Concentration: 8,700.0% in FY2025, up 800.0 pts from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-04) ↗
Reported in Form 10-K Note — Concentration of Credit Risk (XBRL).
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Customer Accounts Receivable Concentration — Top Specialty Distributors Share of Trade AR [annual] (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8,700.0% | +800.0 pts | Form 10-K (filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 7,900.0% | -400.0 pts | Form 10-K (filed 2026-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 8,300.0% | -300.0 pts | Form 10-K (filed 2025-02-05) ↗ |
| FY2022 | Dec 31, 2022 | 8,600.0% | -500.0 pts | Form 10-K (filed 2024-02-05) ↗ |
| FY2021 | Dec 31, 2021 | 9,100.0% | -200.0 pts | Form 10-K (filed 2023-02-06) ↗ |
| FY2020 | Dec 31, 2020 | 9,300.0% | -400.0 pts | Form 10-K (filed 2022-02-07) ↗ |
| FY2019 | Dec 31, 2019 | 9,700.0% | -200.0 pts | Form 10-K (filed 2021-02-08) ↗ |
| FY2018 | Dec 31, 2018 | 9,900.0% | 0.0 pts | Form 10-K (filed 2020-02-07) ↗ |
| FY2017 | Dec 31, 2017 | 9,900.0% | – | Form 10-K (filed 2019-02-07) ↗ |
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Customer Accounts Receivable Concentration (%), annual FY2017–FY2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/conc-ar-top-cust
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?